Research graph
References from A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist. Local targets link to admitted publications; unresolved targets remain external evidence.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
10.1182/blood.2022016867 · 2022 · External reference
Older patients with acute myeloid leukemia deserve individualized treatment
10.1007/s11912-022-01299-9 · 2022 · External reference
Deficient proliferation and expansion in vitro of two bone marrow cell populations from patients with acute myeloid leukemia in response to hematopoietic cytokines
10.1080/10428190500465424 · 2006 · External reference
Addressing a pre‐clinical pipeline gap: development of the pediatric acute myeloid leukemia patient‐derived xenograft program at Texas Children's Hospital at Baylor College of Medicine
10.3390/biomedicines12020394 · 2024 · External reference
Genetic and transcriptional evolution alters cancer cell line drug response
10.1038/s41586-018-0409-3 · 2018 · External reference
Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines
10.1038/s41375-024-02400-w · 2025 · External reference
A pan‐cancer survey of cell line tumor similarity by feature‐weighted molecular profiles
10.1016/j.crmeth.2021.100039 · 2021 · External reference
Unresolved reference
2004 · External reference
Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies
10.1158/2159-8290.cd-22-0199 · 2023 · External reference
Conservation of copy number profiles during engraftment and passaging of patient‐derived cancer xenografts
10.1038/s41588-020-00750-6 · 2021 · External reference
Comprehensive characterization of 536 patient‐derived xenograft models prioritizes candidates for targeted treatment
10.1038/s41467-021-25177-3 · 2021 · External reference
PDX models for functional precision oncology and discovery science
2025 · External reference
Using PDX for preclinical cancer drug discovery: the evolving field
10.3390/jcm7030041 · 2018 · External reference
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
10.1038/nm0797-730 · 1997 · External reference
Acute myeloid leukaemia disrupts endogenous myelo‐erythropoiesis by compromising the adipocyte bone marrow niche
10.1038/ncb3625 · 2017 · External reference
Chemotherapy‐resistant human AML stem cells home to and engraft within the bone‐marrow endosteal region
10.1038/nbt1350 · 2007 · External reference
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
10.1038/nature22993 · 2017 · External reference
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging
10.1371/journal.pone.0120925 · 2015 · External reference
The ARRIVE guidelines 2.0: updated guidelines for reporting animal research
10.1371/journal.pbio.3000410 · 2020 · External reference
The sex inclusive research framework to address sex bias in preclinical research proposals
10.1038/s41467-025-58560-5 · 2025 · External reference
In vivo evaluation of leukemic stem cells through the xenotransplantation model
2008 · External reference
Long‐term observation reveals high‐frequency engraftment of human acute myeloid leukemia in immunodeficient mice
10.3324/haematol.2016.153528 · 2017 · External reference
PDX‐MI: minimal information for patient‐derived tumor xenograft models
10.1158/0008-5472.can-17-0582 · 2017 · External reference
Unresolved reference
2021 · External reference
The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice
10.1007/s00432-018-2652-2 · 2018 · External reference
An improved protocol for establishment of AML patient‐derived xenograft models
10.1016/j.xpro.2020.100156 · 2020 · External reference
Acute myeloid leukemia xenograft success prediction: saving time
10.1016/j.exphem.2017.12.002 · 2018 · External reference
Comparison of clonal architecture between primary and immunodeficient mouse‐engrafted acute myeloid leukemia cells
10.1038/s41467-022-29304-6 · 2022 · External reference
Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model
10.1038/sj.leu.2401777 · 2000 · External reference
A robust xenotransplantation model for acute myeloid leukemia
10.1038/leu.2009.143 · 2009 · External reference
Influence of donor‐recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation
10.1002/hem3.80 · 2024 · External reference
Recipient sex and donor leukemic cell characteristics determine leukemogenesis in patient‐derived models
10.3324/haematol.2023.284647 · 2025 · External reference
The public repository of xenografts enables discovery and randomized phase II‐like trials in mice
10.1016/j.ccell.2016.03.008 · 2016 · External reference
Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome
10.1002/ijc.28170 · 2013 · External reference
The molecular subtype of adult acute lymphoblastic leukemia samples determines the engraftment site and proliferation kinetics in patient‐derived xenograft models
10.3390/cells11010150 · 2022 · External reference
The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor
10.1038/s41375-022-01788-7 · 2023 · External reference
Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA‐matched transplantation: occurrence, risk factors, relapse patterns, and outcome
10.1007/s00277-023-05281-8 · 2023 · External reference
How I treat extramedullary acute myeloid leukemia
10.1182/blood-2011-04-347229 · 2011 · External reference
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
10.1182/blood-2009-11-254441 · 2010 · External reference
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
10.1038/s41375-022-01613-1 · 2022 · External reference
Current status and future perspectives in targeted therapy of NPM1‐mutated AML
10.1038/s41375-022-01666-2 · 2022 · External reference
Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A‐rearranged acute myeloid leukemia: a study by the International Berlin‐Frankfurt‐Münster Study Group
10.1200/jco.22.02120 · 2023 · External reference
Cytogenetic and molecular genetic characterization of KMT2A‐PTD positive acute myeloid leukemia in comparison to KMT2A‐rearranged acute myeloid leukemia
10.1016/j.cancergen.2019.10.006 · 2020 · External reference
Patient‐derived xenografts undergo mouse‐specific tumor evolution
10.1038/ng.3967 · 2017 · External reference
Functional heterogeneity of genetically defined subclones in acute myeloid leukemia
10.1016/j.ccr.2014.01.031 · 2014 · External reference
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
10.1016/j.ccell.2022.07.002 · 2022 · External reference
Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: an exome sequencing study of 50 patients
10.1158/1078-0432.ccr-17-2344 · 2018 · External reference
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
10.1038/s41375-023-01884-2 · 2023 · External reference
Prime‐seq, efficient and powerful bulk RNA sequencing
10.1186/s13059-022-02660-8 · 2022 · External reference
A clinically applicable gene expression‐based score predicts resistance to induction treatment in acute myeloid leukemia
10.1182/bloodadvances.2021004814 · 2021 · External reference
A 29‐gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
10.3324/haematol.2017.178442 · 2018 · External reference
Hierarchical classification of hematologic malignancies using epigenetic and genetic information
2026 · External reference
Rapid epigenomic classification of acute leukemia
10.1038/s41588-025-02321-z · 2025 · External reference
In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice
10.1371/journal.pone.0052798 · 2012 · External reference
Combined proteomics and CRISPR–Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
10.1186/s12943-023-01803-0 · 2023 · External reference
In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets
10.1038/s41467-021-25963-z · 2021 · External reference
WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice
10.1182/blood.2022016411 · 2023 · External reference
Accelerated regrowth of non‐small‐cell lung tumours after induction chemotherapy
10.1038/sj.bjc.6601418 · 2003 · External reference
Repopulation of cancer cells during therapy: an important cause of treatment failure
10.1038/nrc1650 · 2005 · External reference
AML treatment: conventional chemotherapy and emerging novel agents
10.1016/j.tips.2024.03.005 · 2024 · External reference
AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model
10.1182/blood-2012-10-464677 · 2013 · External reference
Chemotherapy‐resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism
10.1158/2159-8290.cd-16-0441 · 2017 · External reference
Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients
10.1186/s13045-022-01232-4 · 2022 · External reference
Venetoclax combined with decitabine or azacitidine in treatment‐naive, elderly patients with acute myeloid leukemia
10.1182/blood-2018-08-868752 · 2019 · External reference
Trends in clinical success rates and therapeutic focus
10.1038/d41573-019-00074-z · 2019 · External reference
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T‐ALL
10.1182/blood.2021014485 · 2022 · External reference
Plasticity in growth behavior of patients' acute myeloid leukemia stem cells growing in mice
10.3324/haematol.2019.226282 · 2020 · External reference
Dynamics of genomic clones in breast cancer patient xenografts at single‐cell resolution
10.1038/nature13952 · 2015 · External reference
Targeting FLT3 with a new‐generation antibody‐drug conjugate in combination with kinase inhibitors for treatment of AML
10.1182/blood.2021015246 · 2023 · External reference
Establishing and maintaining an extensive library of patient‐derived xenograft models
10.3389/fonc.2018.00019 · 2018 · External reference
Cancer models in preclinical research: a chronicle review of advancement in effective cancer research
10.1002/ame2.12165 · 2021 · External reference
Current status and perspectives of patient‐derived xenograft models in cancer research
10.1186/s13045-017-0470-7 · 2017 · External reference
A primary hierarchically organized patient‐derived model enables in depth interrogation of stemness driven by the coding and non‐coding genome
10.1038/s41375-022-01697-9 · 2022 · External reference
Integrative single‐cell expression and functional studies unravels a sensitization to cytarabine‐based chemotherapy through HIF pathway inhibition in AML leukemia stem cells
10.1002/hem3.45 · 2024 · External reference
Advances in the application of patient‐derived xenograft models in acute leukemia resistance
2025 · External reference
Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action
10.3389/fonc.2022.960317 · 2022 · External reference
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo‐resistance
10.1038/s41375-022-01726-7 · 2022 · External reference
